Pertuzumab,Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Pertuzumab,Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle, 2023, version number 5, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/507.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
Pertuzumab is indicated in combination with trastuzumab and PACLitaxel in adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease where patients are intolerant of, have had significant toxicity to or are deemed clinically unsuitable for DOCEtaxel	1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Pertuzumab, Trastuzumab